Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Ready To Oppose Possible FDA Action On Weight-Loss Petition

This article was originally published in The Tan Sheet

Executive Summary

FDA likely will not act soon on a controversial petition to consider weight-loss claims by dietary supplements as disease claims, industry stakeholders say

You may also be interested in...



Weight loss supplements as entertainment

HBO's newly acquired pilot "Fat Sells" takes on the $46 billion weight-loss supplement industry in an attempt to break "wide open" a "world not regulated by the FDA," says Dave Broome, co-creator of the one-hour drama. The pilot will explore body image, self-esteem and power in a culture "obsessed with looks and weight" where "everyone is looking for that Magic Pill," he says in a July 10 release. The announcement comes three months after GlaxoSmithKline, the maker of the alli OTC weight loss medication, filed a citizen petition asking FDA to require pre-market approval for supplements making weight-loss claims ("1The Tan Sheet," May 19, 2008, p. 4). GSK marketing for the product stresses alli is "a program, not a pill," and users must make meaningful diet and lifestyle changes in order for the product to work (2"The Tan Sheet" Feb. 12, 2007, p. 8)...

Weight loss supplements as entertainment

HBO's newly acquired pilot "Fat Sells" takes on the $46 billion weight-loss supplement industry in an attempt to break "wide open" a "world not regulated by the FDA," says Dave Broome, co-creator of the one-hour drama. The pilot will explore body image, self-esteem and power in a culture "obsessed with looks and weight" where "everyone is looking for that Magic Pill," he says in a July 10 release. The announcement comes three months after GlaxoSmithKline, the maker of the alli OTC weight loss medication, filed a citizen petition asking FDA to require pre-market approval for supplements making weight-loss claims ("1The Tan Sheet," May 19, 2008, p. 4). GSK marketing for the product stresses alli is "a program, not a pill," and users must make meaningful diet and lifestyle changes in order for the product to work (2"The Tan Sheet" Feb. 12, 2007, p. 8)...

Weight loss supplements as entertainment

HBO's newly acquired pilot "Fat Sells" takes on the $46 billion weight-loss supplement industry in an attempt to break "wide open" a "world not regulated by the FDA," says Dave Broome, co-creator of the one-hour drama. The pilot will explore body image, self-esteem and power in a culture "obsessed with looks and weight" where "everyone is looking for that Magic Pill," he says in a July 10 release. The announcement comes three months after GlaxoSmithKline, the maker of the alli OTC weight loss medication, filed a citizen petition asking FDA to require pre-market approval for supplements making weight-loss claims ("1The Tan Sheet," May 19, 2008, p. 4). GSK marketing for the product stresses alli is "a program, not a pill," and users must make meaningful diet and lifestyle changes in order for the product to work (2"The Tan Sheet" Feb. 12, 2007, p. 8)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel